Jason E Toombs Selected Research

apricoxib

9/2012	Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer.
9/2012	Epithelial-mesenchymal transition increases tumor sensitivity to COX-2 inhibition by apricoxib.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jason E Toombs Research Topics

Disease

18	Neoplasms (Cancer) 01/2022 - 05/2009
8	Neoplasm Metastasis (Metastasis) 01/2022 - 02/2010
7	Pancreatic Neoplasms (Pancreatic Cancer) 01/2022 - 02/2010
4	Adenocarcinoma 01/2022 - 01/2011
2	Lung Neoplasms (Lung Cancer) 05/2016 - 11/2012
2	Carcinogenesis 01/2012 - 08/2010
1	Anemia 01/2021
1	Communicable Diseases (Infectious Diseases) 01/2021
1	Hemolysis 01/2021
1	Melanoma (Melanoma, Malignant) 01/2016
1	Ascites 01/2016
1	Thrombosis (Thrombus) 09/2015
1	Disease Progression 02/2014
1	Hypoxia (Hypoxemia) 02/2014
1	Adenocarcinoma of Lung 10/2013
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 09/2012
1	Carcinoma (Carcinomatosis) 09/2012
1	Colorectal Neoplasms (Colorectal Cancer) 09/2012
1	Pathologic Neovascularization 08/2010
1	Breast Neoplasms (Breast Cancer) 11/2009

Drug/Important Bio-Agent (IBA)

5	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2014 - 05/2009
4	Gemcitabine FDA Link 01/2022 - 04/2010
4	Proteins (Proteins, Gene)FDA Link 05/2016 - 01/2011
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2022 - 01/2018
2	PhosphatidylserinesIBA 01/2021 - 05/2016
2	Antineoplastic Agents (Antineoplastics)IBA 12/2015 - 09/2012
2	Cell Surface ReceptorsIBA 02/2014 - 08/2010
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 11/2012 - 05/2009
2	apricoxibIBA 09/2012 - 09/2012
1	Immune Checkpoint InhibitorsIBA 01/2022
1	Programmed Cell Death 1 ReceptorIBA 01/2022
1	dubermatinibIBA 01/2022
1	RNA (Ribonucleic Acid)IBA 01/2021
1	c-Mer Tyrosine KinaseIBA 01/2021
1	NucleosidesIBA 01/2018
1	bemcentinibIBA 01/2018
1	Phosphotransferases (Kinase)IBA 01/2018
1	phosphatidylethanolamineIBA 05/2016
1	CarbohydratesIBA 05/2016
1	Peptides (Polypeptides)IBA 05/2016
1	Phosphatidic Acids (Phosphatidic Acid)IBA 05/2016
1	Phosphatidylcholines (Phosphatidylcholine)IBA 05/2016
1	PhosphatidylglycerolsIBA 05/2016
1	Phosphatidylinositols (Phosphatidylinositol)IBA 05/2016
1	Docetaxel (Taxotere)FDA Link 05/2016
1	Phospholipids (Phosphatides)FDA LinkGeneric 05/2016
1	SphingomyelinsIBA 05/2016
1	PeptoidsIBA 05/2016
1	LipidsIBA 05/2016
1	tris(dibenzylideneacetone)dipalladiumIBA 01/2016
1	PalladiumIBA 01/2016
1	IntegrinsIBA 12/2015
1	Vitamin K FDA Link 09/2015
1	Warfarin (Coumadin)FDA LinkGeneric 09/2015
1	Axl Receptor Tyrosine KinaseIBA 09/2015
1	CollagenIBA 02/2014
1	Indicators and Reagents (Reagents)IBA 10/2013
1	olaratumabIBA 11/2012
1	platelet-derived growth factor AIBA 11/2012
1	Monoclonal AntibodiesIBA 11/2012
1	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 11/2012
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 09/2012
1	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 09/2012
1	Angiotensin II Type 1 Receptor BlockersIBA 01/2012
1	Losartan (Cozaar)FDA LinkGeneric 01/2012
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 08/2010
1	Neuropilin-1IBA 08/2010
1	LigandsIBA 02/2010
1	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 02/2010
1	Biomarkers (Surrogate Marker)IBA 11/2009
1	CytokinesIBA 11/2009
1	Interleukin-6 (Interleukin 6)IBA 11/2009
1	Bevacizumab (Avastin)FDA Link 05/2009

Therapy/Procedure

9	Therapeutics 01/2022 - 11/2009
5	Drug Therapy (Chemotherapy) 01/2018 - 04/2010
1	Blood Transfusion (Blood Transfusions) 05/2009